- Home
- KRP vs SPRY Comparison
KRP vs SPRY Comparison
Compare KRP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRP | SPRY |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 946.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRP | SPRY |
|---|---|---|
| Price | $11.55 | $11.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $17.50 | ★ $31.25 |
| AVG Volume (30 Days) | 789.2K | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 14.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,520,668.00 | $142,772,000.00 |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $0.92 | $127.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $10.98 | $6.66 |
| 52 Week High | $16.59 | $18.90 |
Technical Indicators
Market Signals| Indicator | KRP | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 62.92 |
| Support Level | $11.31 | $9.78 |
| Resistance Level | $11.59 | $11.50 |
| Average True Range (ATR) | 0.26 | 0.73 |
| MACD | -0.05 | 0.12 |
| Stochastic Oscillator | 13.29 | 90.17 |
Price Performance
Historical ComparisonAbout KRP Kimbell Royalty Partners
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.